CPC C07K 16/32 (2013.01) [A61K 31/573 (2013.01); A61K 39/39558 (2013.01); A61K 45/06 (2013.01); A61K 47/6881 (2017.08); C07K 16/283 (2013.01); C07K 16/2809 (2013.01); C07K 16/2827 (2013.01); C07K 16/2863 (2013.01); C07K 16/2887 (2013.01); C07K 16/2896 (2013.01); C07K 16/30 (2013.01); A61K 2039/505 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/33 (2013.01); C07K 2317/34 (2013.01); C07K 2317/522 (2013.01); C07K 2317/524 (2013.01); C07K 2317/526 (2013.01); C07K 2317/54 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/622 (2013.01); C07K 2317/71 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01)] | 56 Claims |
1. A method of treating or delaying progression of a HER2-positive cancer in a subject, the method comprising administering to the subject an effective amount of a bispecific antibody that binds to HER2 and CD3, wherein the bispecific antibody comprises
(a) an anti-HER2 arm comprising a first binding domain, the first binding domain comprising:
a hypervariable region (HVR)-H1 comprising the amino acid sequence of SEQ ID NO: 169,
an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 170,
an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 171,
an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 172,
an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 173, and
an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 174; and
(b) an anti-CD3 arm comprising a second binding domain, the second binding domain comprising:
an HVR-H1 comprising the amino acid sequence of SEQ ID NO: 1,
an HVR-H2 comprising the amino acid sequence of SEQ ID NO: 2,
an HVR-H3 comprising the amino acid sequence of SEQ ID NO: 3,
an HVR-L1 comprising the amino acid sequence of SEQ ID NO: 4,
an HVR-L2 comprising the amino acid sequence of SEQ ID NO: 5, and
an HVR-L3 comprising the amino acid sequence of SEQ ID NO: 6.
|